On August 27, 2020, the Company hosted a conference call and live webcast to discuss its financial results for the quarter and fiscal year ended June 30, 2020 with investors and analysts (the “Earnings Call”). At approximately 38:07 during the Earnings Call recording and page 12 of the Earnings Call transcript, in response to a question from a participant, we stated that we have been selling our products containing virginiamycin in Brazil under regulatory approvals containing therapeutic claims for approximately one year. More accurately, we are more than one year into a transition period established by the regulatory authorities in Brazil to cease using growth promotion claims for certain products, including products containing virginiamycin. We are in the process of seeking therapeutic claims for these products in Brazil. We expect our ability to sell these products under the current growth promotion claims will continue during this transition period.